Portal vein embolization: rationale, outcomes, controversies and future directions.
Portal vein embolization (PVE) is now considered the standard of care to improve safety for patients undergoing extensive hepatectomy with an anticipated small future liver remnant (FLR). PVE is used to induce contralateral liver hypertrophy in preparation for major liver resection. Optimal patient selection is essential to maximize the clinical benefits of PVE. Computed tomography volumetry is used to calculate a standardized FLR and determine the need for preoperative PVE. Percutaneous PVE can be performed via the transhepatic ipsilateral or contralateral approaches, depending on operator preference. Several different embolic agents are available to the interventional radiologist, all with similar effectiveness in inducing hypertrophy. When an extended hepatectomy is planned, right PVE should include segment 4, in order to maximize FLR hypertrophy. Multiple studies have demonstrated the beneficial outcomes of PVE in both patients with healthy livers and with underlying liver diseases. Novel improvements to PVE should expand its scope to patients who were previously not candidates for the procedure.
Avritscher
Rony
R
University of Texas MD Anderson Cancer Center, TX 77030-4009 , USA.
Duke
Eugene
E
Madoff
David C
DC
D004621:Embolization, Therapeutic / Q000009:adverse effects; D006498:Hepatectomy / Q000009:adverse effects; D006801:Humans; D008099:Liver / Q000098:blood supply / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery*; D008115:Liver Regeneration; D018579:Patient Selection; D011169:Portal Vein / Q000000981:diagnostic imaging; D015641:Radiography, Interventional; D018570:Risk Assessment; D016896:Treatment Outcome